Related references
Note: Only part of the references are listed.GM-CSF Mouse Bone Marrow Cultures Comprise a Heterogeneous Population of CD11c+MHCII+ Macrophages and Dendritic Cells
Julie Helft et al.
IMMUNITY (2015)
Anti-PD-1 Therapy in Melanoma
Blanca Hornet Moreno et al.
SEMINARS IN ONCOLOGY (2015)
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study
Luana Calabro et al.
LANCET RESPIRATORY MEDICINE (2015)
Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy
Alison M. McDonnell et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2015)
The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40
Andrea Khong et al.
BMC CANCER (2014)
Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales
A. Linton et al.
BRITISH JOURNAL OF CANCER (2014)
Is cancer vaccination feasible at older age?
Claudia Gravekamp et al.
EXPERIMENTAL GERONTOLOGY (2014)
CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
Patrick A. Ott et al.
CLINICAL CANCER RESEARCH (2013)
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
Luana Calabro et al.
LANCET ONCOLOGY (2013)
Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity
W. Joost Lesterhuis et al.
PLOS ONE (2013)
Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression
Raffit Hassan et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Immunity and malignant mesothelioma: From mesothelial cell damage to tumor development and immune response-based therapies
Valerio Izzi et al.
CANCER LETTERS (2012)
IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase
Connie Jackaman et al.
INTERNATIONAL IMMUNOLOGY (2012)
The Use of Agonistic Anti-CD40 Therapy in Treatments for Cancer
Andrea Khong et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2012)
Inhibition of dendritic cell migration by transforming growth factor-β1 increases tumor-draining lymph node metastasis
Kazuhiro Imai et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2012)
Age-Related Oxidative Stress Compromises Endosomal Proteostasis
Elvira S. Cannizzo et al.
CELL REPORTS (2012)
CD40-activated B cells contribute to mesothelioma tumor regression
Connie Jackaman et al.
IMMUNOLOGY AND CELL BIOLOGY (2011)
Partial restoration of T-cell function in aged mice by in vitro blockade of the PD-1/PD-L1 pathway
Celine S. Lages et al.
AGING CELL (2010)
Pancreatic adenocarcinoma exerts systemic effects on the peripheral blood myeloid and plasmacytoid dendritic cells: an indicator of disease severity?
Vegard Tjomsland et al.
BMC CANCER (2010)
High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy
Steven C. H. Kao et al.
CLINICAL CANCER RESEARCH (2010)
Therapeutic influence on circulating and monocyte-derived dendritic cells in laryngeal squamous cell carcinoma patients
Xiao Jie Ma et al.
ACTA OTO-LARYNGOLOGICA (2009)
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases
Anna Maria Di Giacomo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
CD1a expression defines an interleukin-12 producing population of human dendritic cells
M. Cernadas et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb
Oihana Murillo et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells
C. Jackaman et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
Locally Administered TLR7 Agonists Drive Systemic Antitumor Immune Responses That Are Enhanced by Anti-CD40 Immunotherapy
Steve A. Broomfield et al.
JOURNAL OF IMMUNOLOGY (2009)
Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients:: CD1c+ dendritic cell frequency predicts progression-free survival
Hester van Cruijsen et al.
CLINICAL CANCER RESEARCH (2008)
Deliberately provoking local inflammation drives tumors to become their own protective vaccine site
Connie Jackaman et al.
INTERNATIONAL IMMUNOLOGY (2008)
Enumeration of blood dendritic cells in patients with multiple myeloma at presentation and through therapy
Simon J. Harrison et al.
LEUKEMIA & LYMPHOMA (2008)
Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling
Scott H. Robbins et al.
GENOME BIOLOGY (2008)
Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer
A. Pinzon-Charry et al.
BRITISH JOURNAL OF CANCER (2007)
Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses
Ingo Fricke et al.
CLINICAL CANCER RESEARCH (2007)
A phase I clinical trial of single-dose intrapleural IFN-β gene transfer for malignant pleural mesothelioma and metastatic pleural effusions:: High rate of antitumor immune responses
Daniel H. Sterman et al.
CLINICAL CANCER RESEARCH (2007)
Tumor-derived factors impaired motility and immune functions of dendritic cells through derangement of biophysical characteristics and reorganization of cytoskeleton
Zhu Zeng et al.
CELL MOTILITY AND THE CYTOSKELETON (2007)
Characterization of circulating blood dendritic cell subsets DCI23+ (lymphoid) and DCIIC+ (myeloid) in prostate adenocarcinoma patients
Alessandro Sciarra et al.
PROSTATE (2007)
Maturation of circulating dendritic cells and imbalance of T-cell subsets in patients with squamous cell carcinoma of the head and neck
K Sakakura et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
From plasmacytoid to dendritic cell: Morphological and functional switches during plasmacytoid pre-dendritic cell differentiation
V. Soumelis et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2006)
Quantitative and functional defects of dendritic cells in classic Kaposi's sarcoma
Silvia Della Bella et al.
CLINICAL IMMUNOLOGY (2006)
Medical progress - Advances in malignant mesothelioma
BWS Robinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy
S Broomfield et al.
CANCER RESEARCH (2005)
Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma
P DeLong et al.
CANCER BIOLOGY & THERAPY (2005)
Antigen-processing machinery in human dendritic cells: Up-regulation by maturation and down-regulation by tumor cells
TL Whiteside et al.
JOURNAL OF IMMUNOLOGY (2004)
Cutting edge: Tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation
PA Stumbles et al.
JOURNAL OF IMMUNOLOGY (2004)
IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature:: A novel mechanism for IL-21
C Jackaman et al.
JOURNAL OF IMMUNOLOGY (2003)
Dysfunctional and short-lived subsets in monocyte-derived dendritic cells from patients with advanced cancer
H Onishi et al.
CLINICAL IMMUNOLOGY (2002)
Mouse and human dendritic cell subtypes
K Shortman et al.
NATURE REVIEWS IMMUNOLOGY (2002)
Generation of interferon α-producing predendritic cell (Pre-DC)2 from human CD34+ hematopoietic stem cells
B Blom et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
In vivo cross-presentation of a soluble protein antigen: Kinetics, distribution, and generation of effector CTL recognizing dominant and subdominant epitopes
D Nelson et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
